LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

LLY

1,023.98

-2.1%↓

JNJ

238.23

-0.2%↓

ABBV

222.29

-0.37%↓

NVS

158.25

+0.92%↑

MRK

117.15

-0.43%↓

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

105.05 0.23

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

103.59

Max

107.57

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.2M

-93M

Pardavimai

33M

265M

Pelno marža

-34.965

Darbuotojai

1,999

EBITDA

6.6M

-82M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+21.82% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-19

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.7B

14B

Ankstesnė atidarymo kaina

104.82

Ankstesnė uždarymo kaina

105.05

Naujienos nuotaikos

By Acuity

50%

50%

149 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-10 23:26; UTC

Pagrindinės rinkos jėgos

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

2026-02-10 22:31; UTC

Uždarbis

Correction to America Movil 4Q Profit Article

2026-02-10 22:22; UTC

Uždarbis

America Movil 4Q Profit Jumps on Lower Financial Costs

2026-02-10 23:51; UTC

Rinkos pokalbiai
Uždarbis

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

2026-02-10 23:42; UTC

Rinkos pokalbiai

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

2026-02-10 23:40; UTC

Rinkos pokalbiai
Uždarbis

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

2026-02-10 23:21; UTC

Rinkos pokalbiai

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

2026-02-10 23:21; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-10 22:17; UTC

Rinkos pokalbiai

Australia's One Nation Now Commands Working Class Vote -- Market Talk

2026-02-10 22:15; UTC

Uždarbis

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

2026-02-10 22:10; UTC

Uždarbis

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

2026-02-10 22:10; UTC

Uždarbis

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

2026-02-10 22:09; UTC

Uždarbis

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

2026-02-10 22:09; UTC

Uždarbis

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

2026-02-10 22:01; UTC

Uždarbis

Intact Financial 4Q EPS C$5.24 >IFC.T

2026-02-10 21:54; UTC

Uždarbis

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

2026-02-10 21:53; UTC

Uždarbis

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

2026-02-10 21:51; UTC

Uždarbis

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

2026-02-10 21:51; UTC

Uždarbis

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

2026-02-10 21:51; UTC

Uždarbis

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

2026-02-10 21:51; UTC

Uždarbis

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

2026-02-10 21:51; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

2026-02-10 21:50; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

2026-02-10 21:50; UTC

Uždarbis

James Hardie Industries 3Q EPS 12c >JHX

2026-02-10 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-10 21:50; UTC

Uždarbis

James Hardie Industries 3Q Adj EPS 24c >JHX

2026-02-10 21:49; UTC

Uždarbis

James Hardie Industries 3Q Sales $1.24B >JHX

2026-02-10 21:49; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

2026-02-10 21:48; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

2026-02-10 21:47; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

21.82% į viršų

12 mėnesių prognozė

Vidutinis 128.33 USD  21.82%

Aukščiausias 175 USD

Žemiausias 105 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

18

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

149 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat